Research into the Monoclonal Antibody GC33 for HCC

Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).

Clinical Pearls

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).

  • GC33 is a humanized monoclonal antibody against GPC3 that is frequently expressed in HCC.
  • In aphase Ib dose escalation study, GC33 was looked at in combination with sorafenib. Though GC33 showed questionable tolerability, the agent will be looked at with a biomarker component in a future trial.
  • Aphase II triallooking at GC33 in previously treated patients with HCC was also negative.